Selective blockade of P2Y12 receptors by prasugrel inhibits myocardial infarction induced by thrombotic coronary artery occlusion in rats

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 3, 2011, Pages 329-334

  Sugidachi, Atsuhiro ^a   Yamaguchi, Shinji ^a   Jakubowski, Joseph A ^b   Ohno, Kosaku ^a   Tomizawa, Atsuyuki ^a   Hashimoto, Masami ^a   Niitsu, Yoichi ^a  

^a DAIICHI SANKYO CO   (Japan)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

ADP; antiplatelet agent; myocardial infarction; P2Y12 receptors; platelet aggregation; prasugrel; thienopyridine

Indexed keywords

ADENOSINE DIPHOSPHATE; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; PURINERGIC P2 RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANTIAGGREGATORY EFFECT; ARTICLE; BINDING ASSAY; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG ACTIVITY; DRUG EFFICACY; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART MUSCLE NECROSIS; HEART RATE; IN VIVO STUDY; IRRADIATION; NONHUMAN; PHOTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BINDING; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; THROMBOSIS; ANIMAL; BLOOD PRESSURE; CORONARY ARTERY THROMBOSIS; DISEASE MODEL; DRUG SCREENING; ELECTROCARDIOGRAPHY; MALE; METABOLISM; PATHOLOGY; PROTEIN BINDING; SPRAGUE DAWLEY RAT; THROMBOCYTE;

ANIMALS; BLOOD PLATELETS; BLOOD PRESSURE; CORONARY OCCLUSION; CORONARY THROMBOSIS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; HEART RATE; MALE; MYOCARDIAL INFARCTION; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTEIN BINDING; PURINERGIC P2 RECEPTOR ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P2Y12; THIOPHENES;

EID: 80052723750     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182244a6f     Document Type: Article

References (29)

1. 12 receptor antagonist activity. Semin Thromb Hemost. 2005;31: 184-194. (Pubitemid 40605193)
2. Jakubowski JA, Winters KJ, Naganuma H, et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev. 2007;25:357-374. (Pubitemid 350233359)
3. Sugidachi A, Asai F, Yoneda K, et al. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747. Br J Pharmacol. 2001;132:47-54. (Pubitemid 32128433)
4. Sugidachi A, Ogawa T, Kurihara A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost. 2007;5: 1545-1551. (Pubitemid 46965386)
5. Li YG, Ni L, Brandt JT, et al. Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. Platelets. 2009;20:316-327.
6. 12 inhibitor. Pharmacotherapy. 2009;29:1089-1102.
7. Wiviott SD, Braunwald E, Mc Cabe CH, et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. NEngl JMed. 2007;357:2001-2015. (Pubitemid 350106708)
8. Zucker MB, Nachmias VT. Platelet activation. Arteriosclerosis. 1985;5: 2-18. (Pubitemid 15171662)
9. 12 receptor. Curr Pharm Des. 2006;12:1255-1259. (Pubitemid 44082134)
10. Kahner BN, Shankar H, Murugappan S, et al. Nucleotide receptor signaling in platelets. J Thromb Haemost. 2006;4:2317-2326. (Pubitemid 44575423)
11. Gachet C. P2 receptors, platelet function and pharmacological implica-tions. Thromb Haemost. 2008;99:466-472. (Pubitemid 351549282)
12. 12/thrombin in ADP- and thrombin-induced human platelet activation. Br J Pharmacol. 2004;142: 1325-1331. (Pubitemid 39178886)
13. Jarvis GE, Humphries RG, Robertson MJ, et al. ADP can induce aggregation of human platelets via both P2Y(1) and P(2T) receptors. Br J Pharmacol. 2000;129:275-282. (Pubitemid 30073900)
14. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the plate-let ADP receptor targeted by antithrombotic drugs. Nature. 2001;409: 202-207. (Pubitemid 32144286)
15. Baurand A, Raboisson P, Freund M, et al. Inhibition ofplatelet functionby administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol. 2001;412:213-221. (Pubitemid 32144936)
16. Hirata Y Umemura K, Uematsu T, et al. An experimental myocardial infarction model in the rat and its properties. Jpn J Pharmacol. 1995;67:51-57.
17. Bal Dit Sollier C, Berge N, Boval B, et al. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel. Thromb Haemost. 2010;104:571-581.
18. Sugidachi A, Asai F, Ogawa T, et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 2000;129:1439-1446. (Pubitemid 30175717)
19. 12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species. Eur J Pharmacol. 2008;579:276-282.
20. 12 inhibitor, in rat models of cerebral and peripheral artery occlusive diseases. Eur J Pharmacol. 2009;612:29-34.
21. 12 in carotid artery lesions. Arterioscler Thromb Vasc Biol. 2010;30:2434-2442.
22. Frelinger AL 3rd, Jakubowski JA, Li Y et al. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: influence of other blood cells, calcium, and aspirin. Thromb Haemost. 2007;98:192-200. (Pubitemid 47074196)
23. 12 receptors by prasugrel. Biochem Pharmacol. 2007;74:1003-1009. (Pubitemid 47284007)
24. 12-mediated platelet function. Thromb Haemost. 2010;103:1210-1217.
25. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res. 1990;60:269-280.
26. Matsuno H, Uematsu T, Nagashima S, et al. Photochemically induced thrombosis model in rat femoral artery and evaluation ofeffects of heparin and tissue-type plasminogen activator with use of this model. J Pharmacol Methods. 1991;25:303-317.
27. Camici GG, Steffel J, Amanovic I, et al. Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents. Eur Heart J. 2010;31:236-242.
28. 12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol. 2007;63:421-430. (Pubitemid 46426638)
29. 2 inhibitor: a multiple-dose study in healthy humans. Platelets. 2006;17: 218-226. (Pubitemid 43890793)